Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice

DNA and Cell Biology

Volumn 23, Issue 6, 2004, Pages 391-394

  Tang, Lin ^a   Zhu, Qingyu ^b   Qin, Ede ^b   Yu, Man ^b   Ding, Zhifen ^c   Shi, Huiying ^c   Cheng, Xiaojie ^a   Wang, Caiping ^a   Chang, Guohui ^b   Zhu, Qiang ^e   Fang, Fang ^e   Chang, Haiyan ^e   Li, Shuangli ^a   Zhang, Xumin ^a   Chen, Xishu ^a   Yu, Jun ^a   Wang, Jian ^a,d   Chen, Ze ^d,e  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b Academy of Military Medicine   (China)

^c Chinese Natl Vacc and Serum Inst   (China)

^d WUHAN INSTITUTE OF VIROLOGY   (China)

^e HUNAN NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; PROPIOLACTONE; SEPHAROSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; FEMALE; IMMUNIZATION; INOCULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SARS CORONAVIRUS; SERUM; SEVERE ACUTE RESPIRATORY SYNDROME; STATISTICAL SIGNIFICANCE; VERO CELL;

ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CHROMATOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE SERA; MICE; MICE, INBRED BALB C; PROPIOLACTONE; SARS VIRUS; VACCINES, INACTIVATED; VERO CELLS; VIRAL VACCINES;

ANIMALIA; CORONAVIRUS; RNA VIRUSES; SARS CORONAVIRUS;

EID: 3042783044     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454904323145272     Document Type: Article

References (20)

1. BATSON, A. (1998). Sustainable introduction of affordable new vaccines: The targeting strategy. Vaccine Suppl, S93-S98.
2. BUDOWSKY, E.I., FRIEDMAN, E.A., and ZHELEZNOVA, N.V. (1991). Principles of selective inactivation of viral genome. VII. Some peculiarities in determination of viral suspension infectivity during inactivation by chemical agents. Vaccine 9, 473-476.
3. BUDOWSKY, E.I., SMIRNOV, Y.U.A., and SHENDEROVICH, S.F. (1993). Principles of selective inactivation of viral genome. VIII. The influence of beta-propiolactone on immunogenic and protective activities of influenza virus. Vaccine 11, 343-348.
4. CASTRO, R.F., and PERLMAN, S. (1995). CD8+ T-cell epitopes within the surface glycoprotein of a neurotropic coronavirus and correlation with pathogenicity. J. Virol. 69, 8127-8131.
5. CHEN, Z., KADOWAKI, S., HAGIWARA, Y., YOSHIKAWA, T., SATA, T., KURATA, T., and TAMURA, S. (2001). Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine 19, 1446-1455.
6. CHEN, Z., SAHASHI, Y., MATSUO, K., ASANUMA, H., TAKAHASHI, H., IWASAKI, T., SUZUKI, Y., AIZAWA, C., KURATA, T., and TAMURA, S. (1998). Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 16, 1544-1549.
7. CLEMENTS, C.J., and GRIFFITHS, E. (2002). The global impact of vaccines containing aluminium adjuvants. Vaccine 20(Suppl3), S24-S33.
8. DYE, C., and GAY, N. (2003). Epidemiology. Modeling the SARS epidemic. Science 300, 1884-1885.
9. ENSERINK, M. (2003). SARS in China. The big question now: Will it be back? Science 301, 299.
10. GUPTA, R.K., RELYVELD, E.H., LINDBLAD, E.B., BIZZINI, B., BEN-EFRAIM, S., and GUPTA, C.K. (1993). Adjuvants - A balance between toxicity and adjuvanticity. Vaccine 11, 293-300.
11. HOHDATSU, T., YAMADA, M., TOMINAGA, R., MAKINO, K., KIDA, K., and KOYAMA, H. (1998). Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus. J. Vet. Med. Sci. 60, 49-55.
12. PEARSON, H., CLARKE, T., ABBOTT, A., KNIGHT, J., and CYRANOSKI, D. (2003). SARS: What have we learned? Nature 424, 121-126.
13. QIN E'DE, ZHU QINGYU, YU MAN, FAN BAOCHANG, CHANG GUOHUI, SI BINGYIN, YANG BAO'AN, PENG WENMING, JIANG TAO, LIU BOHUA. et al. (2003). A complete sequence and comparative analysis of a SARS-associated virus (Isolate BJ01). Chin. Sci. Bull. 48, 941-948.
14. RAPPUOLI, R., MILLER, H.I., and FALKOW, S. (2002). Medicine. The intangible value of vaccination. Science 297, 937-939.
15. ROTA, P.A., OBERSTE, M.S., MONROE, S.S., NIX, W.A., CAMPAGNOLI, R., ICENOGLE, J.P., PENARANDA, S., BANKAMP, B., MAHER, K., CHEN, M.H. et al. (2003). Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394-1399.
16. RUEF, C. (2003). SARS - A fast moving infectious disease. Infection 31, 135.
17. SMITH, A.L., DE SOUZA, M.S., FINZI, D., and BARTHOLD, S.W. (1992). Responses of mice to murine coronavirus immunization. Arch. Virol. 125, 39-52.
18. STEPHAN, W., DICHTELMULLER, H., PRINCE, A.M., BROTMAN, B., and HUIMA, T. (1988). Inactivation of the Hutchinson strain of hepatitis non-A, non-B virus in intravenous immunoglobulin by beta-propiolactone. J. Med. Virol. 26, 227-232.
19. THEODORE, C.E., and MARTIN, M. (2002). Workshop summary: Aluminum in vaccines. Vaccine 20, S1-S4.
20. WU, G.F., DANDEKAR, A.A., PEWE, L., and PERLMAN, S. (2000). CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination. J. Immunol. 165, 2278-2286.